ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Dec. 11, 2024 /PRNewswire/ -- ADC... Read More

Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of 91% and 70% CR LAUSANNE, Switzerland , Dec. 9, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage... Read More

Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland , Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024 , at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA ®... Read More

LAUSANNE , Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the... Read More

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA ® Phase 2 IIT data in indolent lymphomas to be presented at the 66 th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Nov. 7, 2024... Read More

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA... Read More

LAUSANNE , Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024 Presentation Time: 11:00 a.m. ET Format: Fireside Chat Speaker: Ameet Mallik , Chief Executive... Read More

LAUSANNE , Switzerland , Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 42,000 of the Company's common shares to two new employees on November 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the... Read More

LAUSANNE , Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024 , at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please... Read More

LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 113,700 of the Company’s common shares to six new employees on October 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the... Read More

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company’s common shares to four new employees on September 3, 2024 (each, a “Grant”). The Grants were offered as material inducement to the... Read More

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September: H.C. Wainwright 26 th Annual Global Investment Conference Date: September 9, 2024 Presentation Time: 7:00 a.m. ET Format: Virtual Fireside Chat Speaker: Ameet Mallik,... Read More

ZYNLONTA ® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland,... Read More

LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 38,600 of the Company’s common shares to three new employees on August 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the... Read More

LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarter 2024 and provide operational updates. To access the conference call, please... Read More

£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to build out Myricx Bio’s proprietary N -Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its... Read More

LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 172,400 of the Company’s common shares to six new employees on July 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board... Read More

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. “We are pleased to be joining the Russell 2000 ® Index,” said Ameet Mallik, Chief... Read More

LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s... Read More

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website at... Read More

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC... Read More

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’... Read More

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per... Read More

ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area... Read More

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ® All patients achieving responses maintained them at the time of data cutoff ZYNLONTA was generally well-tolerated and safety was consistent with known profile Data were presented at Lymphoma Research Foundation’s 2024 Marginal Zone... Read More

LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company’s common shares to four new employees on May 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board... Read More

LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress against key catalysts from the pipeline. To access the conference call, please register here . Registrants will receive the dial-in... Read More

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been initiated LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose... Read More

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company’s novel exatecan-based... Read More

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the... Read More

ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21% 1... Read More

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website... Read More

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates. To access the conference call, please register here . Registrants will receive the dial-in number and... Read More

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American... Read More

LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 at 9:50 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website,... Read More

LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The... Read More

ZYNLONTA ® 1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort​ with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination Multiple data catalysts... Read More

Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate... Read More

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N -Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur,... Read More

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at... Read More

3Q 2023 ZYNLONTA ® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23% 2 year-over-year due to portfolio prioritization and operational efficiencies; Expected cash runway into mid-2025 Prioritized pipeline progressing with initial data readouts from LOTIS-7 and studies of ADCT-601... Read More

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14 th at 10:00 a.m. GMT. A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website,... Read More

Presentations to highlight clinical utility of ZYNLONTA ® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating ZYNLONTA in combination with rituximab in patients with r/r follicular lymphoma LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA... Read More

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for the third quarter 2023 and provide business updates. To access the conference call, please register here . Registrants will receive the dial-in number and unique PIN. It is recommended that... Read More

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO). Dr. Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its... Read More

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September. Details of the events are as follows: Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m. ET Cantor Global Healthcare Conference - fireside chat on... Read More

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA ® in patients with r/r non-Hodgkin lymphoma to be highlighted in poster; actively enrolling patients in bispecific combination arms LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today... Read More

2Q 2023 ZYNLONTA ® 1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20% 2 year-over-year due to portfolio prioritization and organizational efficiencies Pipeline advancing with initial data readouts from the clinical trials of LOTIS-7, ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 2024 Company to host conference... Read More

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates. To access the conference call, please register here . Registrants will receive the dial-in number and unique PIN. It is recommended that... Read More

BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA ® (loncastuximab tesirine-lpyl), which is seeking an indication for the... Read More

LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Given the challenges of defining the addressable segment of the difficult-to-treat unfit... Read More

LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (ClinicalTrials.gov Identifier: NCT05144009) evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The voluntary... Read More

Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the election of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial... Read More

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will also be... Read More

LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8 th at 8:30 a.m. EDT. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website,... Read More

Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA® LAUSANNE, Switzerland / May 11, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been... Read More

LAUSANNE, Switzerland / May 10, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16 th at 10:00 a.m. EDT. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC... Read More

1Q 2023 ZYNLONTA ®1 net sales increased 15% and operating expenses decreased 19% year-over-year 2 ; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating expenses as compared to FY 2022 Implementing new go-to-market model to help drive growth in both academic and community centers Later-stage pipeline programs continue to progress with several initial data readouts expected in the... Read More

LAUSANNE, Switzerland / May 02, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates. To access the conference call, please register here . Registrants will receive the dial-in number and unique PIN. It is recommended that you join... Read More

LAUSANNE, Switzerland / Mar 15, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”). ADC Therapeutics’ Annual Report on Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investors section of the Company’s website at... Read More

LAUSANNE, Switzerland / Mar 01, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43 rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website,... Read More

LAUSANNE, Switzerland / Feb 28, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates. “We made good progress across the business in 2022, including laying the crucial groundwork for the ongoing ZYNLONTA launch. This year, we expect to grow ZYNLONTA net product sales by a double-digit percentage... Read More

LAUSANNE, Switzerland / Feb 21, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates. To access the conference call, please register here . Registrants will receive the dial-in number and unique PIN. It is... Read More

LAUSANNE, Switzerland / Feb 02, 2023 / Business Wire / ADC Therapeutics SA (“ADCT” or the “Company”) (NYSE: ADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates, today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the “Selling... Read More

LAUSANNE, Switzerland / Feb 01, 2023 / Business Wire / ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February. Details of the events are as follows: Guggenheim Healthcare Talks – Oncology Day, fireside chat on Wednesday, February 8 th from 3:55 p.m. – 4:20 p.m. ET SVB Securities Global Biopharma Conference (virtual), corporate... Read More

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11 th at 3:00 p.m. PT. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com . A replay of... Read More

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues... Read More

Approval triggers $50 million milestone payment to ADC Therapeutics ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi ® ) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA ® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in... Read More

Freenome's comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2022 /PRNewswire/ -- Freenome , a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans . Freenome's multiomics platform allows researchers to look across multiple... Read More